The buzz: This Barcelona startup only launched in 2010, but it is focused on a vital area for diagnostics: developing quicker tests for infectious diseases, antibiotic resistance and critically ill patients. And its approach blends molecular diagnostic and immunoassay technology into a single device. A benefit here: speed. The company envisions its test providing results in 30 minutes or less, versus several days under current technology.
Milestone: Earlier in May, the company raised a $22.1 million Series B funding round from Kurma Life Sciences Partners, Idinvest, Boehringer Ingelheim Venture Fund and Caixa Capital Risc, among a distinguished roster of investors. And plans call for using the cash to advance development of the technology, with an eye toward a 2015 commercial launch. Their rapid development cycle drew investor interest, and we'll be watching to see if their technology continues to wow as it crosses its remaining development hurtles.
Spanish Dx startup grabs a $22.1 M Series B